Recent Company News

• 08:51 AM ET Dec 05, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:34 PM ET Dec 04, 2025
  

  Nippon Shinyaku upgraded to overweight from neutral at JPMorgan (¥4323.0000, 0)

• 06:33 PM ET Dec 04, 2025
  

  Nippon Shinyaku upgraded to outperform from neutral at Daiwa (¥4323.0000, 0)

• 01:07 AM ET Dec 04, 2025
  

  UCB will present 21 abstracts at the American Epilepsy Society (AES) Annual Meeting 5-9 Dec (€239.80, 0.00)

• 07:25 AM ET Dec 03, 2025
  

  Follow-up: Capricor Therapeutics announces pivotal Phase 3 HOPE-3 study of Deramiocel in DMD met primary endpoint and key secondary cardiac endpoint ($6.36, 0.00)

• 10:05 PM ET Nov 13, 2025
  

  Nippon Shinyaku reports H1 net income attributable ¥15.76B vs guidance ¥12.80B and FactSet ¥12.90B [1 est] (¥3381.0000, +24)

• 09:18 AM ET Nov 03, 2025
  

  Capricor Therapeutics publishes peer-reviewed study in Biomedicines of its investigational cell therapy, Deramiocel ($6.51, 0.00)

• 01:02 AM ET Nov 03, 2025
  

  Genentech's Gazyva announces Phase III ALLEGORY study of of Gazyva (obinutuzumab) met its primary endpoint (CHF 258.90, 0.00)

• 02:05 AM ET Oct 28, 2025
  

  Roche's Genentech announces Phase III INShore study of Gazyva (obinutuzumab) met its primary endpoint (CHF 267.40, 0.00)

• 01:02 AM ET Oct 20, 2025
  

  FDA approves Genentech's Gazyva to treat LN (CHF 283.70, 0.00)